Ten different drugs continued to kill cancer cells even when their target proteins were removed.
A retrospective study investigated whether safety and efficacy of generic imatinib is similar to the original form in the treatment of CML.
Mortality risk significantly higher for patients with 20 to 29 percent versus less than 20 percent blasts.
Using validated assessment tools, researchers compared patients’ perceptions of HRQOL while undergoing treatment for CML with 1 of 2 TKIs.
An assessment of a population of patients with CML revealed that some are not receiving guideline-based treatment, including TKIs.